Search
Ritobegron
go.drugbank.com/drugs/DB12080InvestigationalRitobegron is under investigation in clinical trial NCT02256735 (Study to Investigate the Effect of KUC 7483 CL on the QT/QTc Interval of the ECG in Comparison to Placebo and Moxifloxacin in Healthy Male and Female Volunteers).
Categories: AmphetaminesAprocitentan
go.drugbank.com/drugs/DB15059ApprovedInvestigational[A263386,L50261] Aprocitentan was approved by the FDA in March 2024 for the treatment of hypertension in patients inadequately controlled with standard therapy.
Omacetaxine mepesuccinate
go.drugbank.com/drugs/DB04865ApprovedInvestigationalWithdrawnThen in March 2006, it received Orphan Drug status from the FDA for the treatment of CML.
Methylone
go.drugbank.com/drugs/DB19192InvestigationalMethylone is under investigation in clinical trial NCT05741710 (A Study to Assess the use of Methylone in the Treatment of PTSD).
Categories: AmphetaminesDarvadstrocel
go.drugbank.com/drugs/DB16581ApprovedInvestigationalWithdrawn[A244524] Darvadstrocel was first approved by the European Commission on March 23, 2018, under the brand name Alofisel. … Perianal fistula is a common manifestation of Crohn’s disease and is often difficult to manage, as it may be associated with complex presentations and symptoms.
Ganaxolone
go.drugbank.com/drugs/DB05087ApprovedInvestigational[L41130] It was approved under the brand name ZTALMY by the US FDA in March 2022 for the treatment of seizures associated with CDKL5 deficiency disorder (CDD), becoming the first FDA-approved treatment … [A3197] Endogenous neurosteroids, which comprise certain metabolites of progesterone and deoxycorticosterone, bind potently and specifically to GABA<sub>A</sub> receptors to enhance their inhibitory effects
Donepezil
go.drugbank.com/drugs/DB00843ApprovedInvestigational[L7916,L7937] A donepezil transdermal delivery system, Adlarity, was approved by the FDA in March 2022 for the treatment of Alzheimer's dementia.
Products: DONEPEZIL ARROW GENERICS, DONEPEZIL DOC GENERICIMirikizumab
go.drugbank.com/drugs/DB14910ApprovedInvestigational[L46237,L46257] Mirikizumab is approved in Japan[L46252] and received a positive opinion from the EMA's Committee for Medicinal Products for Human Use in March 2023.
Isatuximab
go.drugbank.com/drugs/DB14811ApprovedInvestigationalAntibodies to watch" list published in "mAb", a peer-reviewed scientific journal dedicated to antibody research,[A38676,A191826,A191829] isatuximab was granted Orphan Drug designation and approved on March